Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Merck KGaA
Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis
December 05, 2023
From
Merck KGaA
Via
Business Wire
Merck KGaA, Darmstadt, Germany Strengthens Oncology Portfolio Through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib
December 04, 2023
From
Merck KGaA
Via
Business Wire
Merck KGaA, Darmstadt, Germany, Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate
October 30, 2023
From
Merck KGaA
Via
Business Wire
Merck KGaA, Darmstadt, Germany, Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery
September 20, 2023
From
Merck KGaA
Via
Business Wire
Initiation of New Patients on Evobrutinib Paused in the U.S.; Fully Enrolled Phase III Evobrutinib Studies Continue
April 12, 2023
From
Merck KGaA
Via
Business Wire
Merck KGaA, Darmstadt, Germany Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates
December 22, 2022
From
Merck KGaA
Via
Business Wire
Merck KGaA, Darmstadt, Germany Aims to Double R&D Productivity in Oncology, Neurology and Immunology to Deliver More Medicines to Patients Faster
November 21, 2022
From
Merck KGaA
Via
Business Wire
Merck KGaA, Darmstadt, Germany, Announces Changes in Operating Model for Healthcare Business Sector
May 18, 2021
From
Merck KGaA
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.